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ABSTRACT 
The ro1e of rat calcitonin gene-related peptide (CGRP), a recently 
characterized vasoactive neuropeptide, in cardiovascular regu-
lation was studied in the conscious rat. Mean arterial pressure 
(MAP), heart rate, cardiac output (thermodilution technique) and 
regional blood flow (directional pulsed Doppler velocimetry) were 
monltored after i.v. or i.c.v. administration of CGRP. Systemic 
administration of CGRP (0.1-10 rvnol/kg i.v.) decreased MAP 
and increased heart rate in a dose-related manner. Cardiac 
output increased (+95 ± 16 ml/minJkg, P < .01) after the 1-
nmol/kg dose. At the lower or higher doses, CGRP produced no 
consistent changes in cardiac output. Total peripheral resistance 
was decreased significantly at the doses of 1 and 1 0 nmoiJkg of 
CGRP. The CGRP i.v. doses of 1 and 10 nmoiJkg lncreased 
mesenteric and hindquarter blood flow to a maximum of +23 ± 
7 and +30 ± 6%, respectively (P < .01 ). An increase in renal 
blood flow (+19 ± 6%, P < .05) and a decrease in renal 
resistance (-15 ± 4%, P < .05) were produced by the 0.1-nmol/ 
kg dose of CGRP which had no effect on MAP; higher doses of 
CGRP tended to decrease renal blood flow. The resistance in all 
vascular beds was decreased by the CGRP doses of 1 and 1 0 
CGRP is a neuropeptide formed from alternative RNA slicing 
processes during calcitonin gene expression in rat and human 
tissues (Amara et aL, 1982; Rosenfeld et aL, 1983; Tschopp et 
al., 1985). CGRP immunoreactivity, frequently colocalized with 
SP, has been demonstrated in blood vessel periadventitial 
nerves, heart, brain and spinal cord of both rate and humane 
(Amara et aL, 1983; Golzman and Mitchell, 1985; Mulderry et 
al., 1985; Rosenfeld et al., 1983; Tschopp et aL, 1985, Lundberg 
et al., 1985; Goodman and lversen, 1986). CGRP can be detected 
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nmoiJkg. The maximum decreases in mesenteric, renal and 
hindquarter vascular resistance after the 1 0-nmol/kg dose were 
-53 ± 3, -42 ± 5 and -48 ± 4%, respectively (P < .01 ). The 
hypotensive and vasodilator responses to CGRP i.v. were sig-
nificantly magnified, and the tachycardia produced by CGRP was 
attenuated in the sinoaortic denervated rats. Atropine (musca-
rinic blockers), propranolol (beta adrenoceptor blocker), cimeti-
dine and pyrilamine (histamine H, and H2 blockers), indomethacin 
(prostaglandin synthesis inhlbitor), BN52021 (platelet activating 
factor antagonist) or a substance P antagonist had no effect on 
the cardiovascular responses elicited by systemic CGRP. CGRP, 
i.c. v. (0.1-1 0 nmoiJkg), induced a modest tachycardia in both 
intact and sinoaortic denervated rats, but was devoid of any 
other cardiovascular effects. The results indicate that CGRP is 
a potent vasodilator of mesenteric, renal and hindquarter skeletal 
muscle blood vessels in the conscious rat. The hypotensive and 
vasodilator actions of circulating CGRP are likely to be mediated 
by direct peripheral Interaction with CGRP receptors on vascular 
smooth muscle, whereas its tachycardic effect seems to involve 
reflex activation of the sympathetic nervous system. 
in the systemic circulation (Wang et aL, 1988; Zaidi et al., 1985), 
and the plasma Ievels of CGRP are increased in endotoxemia 
(Wang et al., 1988) or after senaory nerve injury (Zaidi et al., 
1985). 
Exogenously administered, rat or human CGRP induces vas-
odilation in human and rabbit skin (Brain et al., 1985; Brain 
and Williams, 1985). In various iaolated vascular tissue prepa-
rations (human pial arteries, feline and rat mesenteric arteries 
or rat aortic strips) CGRP produces vasodilation (Hanko et al., 
1985; Marshall et al., 1986a; Brain et al., 1985). Intravenous 
adminiatration of CO RP producea atrong doae- related hypoten. 
aive and tacbycardic responses both in the rat ( Fisher et al., 
1983; DiPette et al., 1987; Lundberg et al., 1985; Marshallet al., 
1986b) and in human subjects (Franco-Cereceda et al., 1987). 
When injected directly into coronary circulation of the intact 
pig, CGRP was shown to produce coronary vasod.ilation (Ezra 
et al., 1987). In a recent study in the rat, the effects of CGRP 
on blood flow (microsphere technique, DiPette et al., 1987) were 
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monitored 2 min after CGRP administration, at a time point 
when the responses were already compensated or retlexly mod-
ified. No attempt has yet been made to investigate the potential 
role of cardiac function in systemic or regional hemodynamic 
responses to CGRP or were the putative mediators of CGRP 
effects on specific blood vessels studied. 
The present report presents our investigation on the systemic 
and regional hemodynamic actions of CGRP in the intact 
conscious rat by utilizing the thermodilution technique for 
cardiac output monitoring, and the pulsed directional Doppler 
velocimetry to monitor continuous blood tlow in the chronically 
instrumented rat. To examine the role of the central nervous 
system in the cardiovascular responses to CGRP, the peptide 
was administered i.c.v. both to intact rats and to SAD rats 
which completely Iack the baroreceptor retlexes. The role of 
other vasoactive substances which might share some similari-
ties to CGRP or mediate its effects on the microcirculation 
were studied by using specific blockers or synthesis inhibitors. 
Materials and Methods 
Male Sprague-Dawley rats (300-360 g) were purchased from Taconic 
Farma (Germantown, NY) and houaed at 22"C with a 12 hr/12 hr light/ 
dark cycle. After aurgical operationa the rats were houaed individually 
in pl88tic capa (21 x 27 x 16 cm, width x length x beight) with food 
and water ad libitum. 
Meuuremeat of cardiac output. Tbe cardiac output W88 meaa-
ured by thermodilution technique aa deacribed previously in detail 
(Oabom et aL, 1986; Silen et aL, 1986, 1988; Unger et aL, 1983; Walker, 
1986). The principle of thia technique ia to produce a cbange in heat 
content of blood at one point of the circulation (right atrium) and 
detect the reaultant change in temperature at a point downatream 
(aacending aorta). Although the cardiac output values obtained by 
thermodilution tend to be somewbat bigher than thoee determined by 
electromagnetic flowmetry (Lappe et aL, 1985; Osbom et al., 1986) or 
by radioactive microsphere method (lshise et aL, 1980); Flaim and Zelis, 
1980), the thermodilution method offen many advantapa, including 
1) the posaibility to do repeated cardiac output recordinga in a conacioua 
chronically instrumented rat and 2) in contrast to Doppler velocimetry 
(Werber et aL, 1984) or electromagnetic flowmetry (Lappe et aL, 1985), 
thermodilution does not require the extensive open ehest aurgery with 
high mortality and prolonged postoperative rec:overy. 
Each rat to undergo cardiac output meaaurements W88 anesthetized 
with an i.m. injection of ketamine (130 mg/kg) and acepromazine (1.3 
mg/kg) and a PE-50 catheter W88 inaerted into the left femoral artery. 
The catheten were tunneled under the akin and exited at the nape of 
the neck. An incision w88 made at the midline of the neck from the 
cricoid to the clavicle, and a PE-50 catheter w88 inaerted into the right 
atrium via the extemal jugular vein. The left common carotid artery 
w88 expoaed and ligated, and a thermiator (MX2-780-33 model THMP 
f 1.5, Teflon reusable, Columbus Instruments, OH) w88 advanced 
through the carotid into the ascending aorta. Placement above the 
aortic valve W88 confirmed in each animal by the ahape of the dilution 
curve before the probe W88 finally sutured to the neck muscles and 
again at the end of experiment. The jugular vein catheter and the 
thermistor Ieads were tunneled under the skin to the nape of the neck. 
All cathetera and the probe wire were secured by a soft spring wire 
attached to the animal's neck using an adhesive collar. Twenty-four 
houra after the aurgery, the arterialline W88 connected to a preuure 
transducer (Narco Bio-Systeme model RP 1500i) attached to a atrain 
gauge coupler (Narco Bio-Systems type 7032). Blood preuure (mean, 
systolic, di88tolic and pulse) and heart rate were recorded continuously 
on a Narcotrace 80 computerized physiograph and sampled automati-
cally at 30- to 60-aec intervala hy a Northatar-Hazeltine computer. 
To obtain me88urements of cardiac output, the aortic thermiator w88 
attached to the computerized Cardiomu II (CMX2-780-k with micro-
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probe option R, Columbualnatruments). The dead apace ofthe venous 
line was fint flushed with 50 ~&1 of 0.9% (w/v) NaCl (aal.ine) at room 
temperature (22"C); alter a brief atabilization period an additional 
~on of 200 ,d normal aali.ne (22"C) was injected rapidly into the 
right atrium using a 1-mlayringe, and the blood temperature monitored 
by the aortic thermiator. The thermodilution curve repreeenting the 
chanp in aortic temperature W88 then calculated by the Cardiomu U. 
A control period of 15 min included two or three cardiac output 
rec:ordinp to test for conaiatency and placement of the probe. Durlog 
tbia time period, control values for blood presaure and heart rate also 
were collected. The timer for automatic data collection was atarted and 
data points for blood preuure, heart rate and cardiac output were 
collected immediately before and 2, 5, 15, 30 and 45 min after CGRP 
injection into the jugular catheter. TPR W88 calculated by dividing tbe 
mean arterial preuure by the cardiac output; values of cardiac output 
and TPR were further inde:a:ed per unit of weigbt (kilograma). Core 
temperature w88 monitored by the aortic thermoprobe before each 
cardiac output meaaurement. 
Meuuremeat of oraan blood tlow. Regional blood flow in hind-
quarter, renal and mesenteric arteriea w88 monitored in a separate 
group of rats by using the directional pulaed Doppler technique. Al-
tbougb not allowing for quantitative blood flow monitoring, tbis method 
ia superior to other available tecbniquea, u 1) it can be used chronically 
in conacious animala, 2) it allows continuous on-line recording of blood 
flow and 3) it can detect inatantaneous, tranaient cbanges in blood flow 
witbin aeconds after drug adminiatration. Haywood and co-worken 
(1981) demonatrated tbat the velocity signala recorded from the Dop-
pler flow probea are directly and reliably proportional to chanpa in 
true volume flow meaaured by electromqnetic flowmetry. 
Each rat to underso regional hemodynamic measurementa wu an-
eathetized with ketamine-acepromazine, and a guide cannula for i.c.v. 
injectiona W88 placed on the sJrull u described below. A midline 
laparotomy w88 then made, and the left renal and superior mesenteric 
arteriea and lower abdominal aorta above its bifurcation were i.eolated 
carefully under a diasecting microscope. Doppler flow probea (Valpey-
Fiaher, Hopkinton, MA) were then sutured loosely around each veasel 
88 deecribed earlier (Haywood et al., 1981; Silen et al., 1988). The 
inaulated wire Ieads were faed to the back musclea, tunneled under the 
back skin to e:a:it at the neck and soldered to a receptacle wbich was 
then attached to the akull usi01 amall screwa and dental acrylic. The 
anima1s were allowed to recover from the aurgery for 7 days. Twenty-
four houn before the experiment the rat was reaneetbetized with 
halotbane (2% in o:a:ygen) and femoral artery and vein catheterized 
with PE-50 tubing. The cathetera were tunneled under the back skin, 
exited at the nape of the neck and secured by a soft spring wire 88 
deacribed above. 
On the day of the experiment, the arterial catheter was connected 
to a pressure tranaducer (Narco) and blood preuure and beart rate 
were recorded continuously on the Narcotrace 80 phyaiograph. A cable 
connecting the blood ßow receptacle and tbe Doppler flowmeter (Uni-
venity of lowa, Bioengineering Facility, model no. MSC-4) waa at-
tached to the animal and the mean blood ßow recorded continuously 
on the phyaiograph. V ascular resiatance was calculated by dividing the 
MAP by blood velocity (Doppler shift in kilohertz) aa deacribed earlier 
(Haywood et al., 1981; Siren et aL, 1988). Changes in blood flow and 
vaacular reaistance are expressed 88 a percentage of control valuea. 
hatracerebroveatricular hajectiou. Rats were aneathetized with 
ketamine-acepromazine (aee above) and placed on a atereotuic device 
(David Kopf Instruments, Tujunga, CA). A atainleu-steel guide can-
nula was inaerted through the skuU and faed with glue (Eutman 910 
Adbeaive). Coordinates for the injectiona into the right lateral brain 
ventricle (i.c.v.) were meaaured from the bregma: AP, -o.s mm and L, 
1.2 mm. After the placement of the i.c.v. cannula, implantation of 
Doppler flow probe& and femoral cathetera was done aa deecribed in 
detail in the previous aection (meaaurement of organ blood flow). On 
the day of the experiment, injectiona of saline or CGRP were made 
using a preme88ured 30-1 (7.5 mm) cannula inaerted into the ventric-
ular space through the guide cannula. Tbe injection cannula was then 
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connected via polyethylene tubing to a Hamilton microliter syringe, 
and a volume of 10 pl of the control or drug solution was injected over 
a period of 30 sec. The proper position of the i.c. v. cannula was 
detennined at the end of each experiment by an injection of dye 
(methylene blue) into the cerebral ventricles. 
Experimental Prolocola 
DoH-reapoue atadi•. The effect of CGRP on systemic and 
regional hemodynamica was studied by injectiona of increasing doses 
ofCGRP (0.1-10 nmol/kg) i.v. or i.c.v. at 30- to 60-min intervals. The 
volume for i.v. injections was 150 pl; for i.c.v. injections, 10 pl. Before 
commencement of CGRP administration each animal received an 
injection of saline i.v. (150 pl) or i.c.v. (10 pl). The reactivity of the 
blood tlow recordings waa first tested in each animal by i.v. injections 
of epinephrine (0.1, 0.3 and 1 pg/kg) and norepinepbrine (0.1, 0.3 and 
11'1/kg). 
Slnoaortic denervation. In aseparate group of rats (n - 8), SAD 
was perfonned according to the method described by Krieger (1964). 
One week before the experiments, the rats were anesthetized with 
ketamine-acepromazine (see above) and given an injection of atropine 
(0.-t mg/rat i.p.). A midventral neck incision waa made and both of the 
carotid sinuaes were exposed. The auperior laryngeal nerve and cervical 
sympathetic chains were cut. Nerve segmenta of 0.5 cm were removed 
to prevent the poeaibility of reconnection; all connective tiuue and 
nervea were stripped from intemal, extemal and common carotid 
arteriea and the occipital and thyroid arteries along 0.5 cm of their 
length extending from the carotid bifurcation region. In addition, the 
vessels were painted with 10% pbenol, and special attention waa 
denoted to avoid damage to the vagus nerve or other nearby structures. 
In addition to the SAD aurgery, guide cannulaa for i.c. v. injections and 
Doppler flow probes were implanted aa described above. Twenty-four 
hours before the experiment, the animals were anesthetized with ha-
lothane (2% in oxygen), and PE-catheten inserted into the left femoral 
artery and vein as described above. The adequacy of the baroreceptor 
deafferentation procedure waa aaseased before any interventiona by 
evaluating the maximal heart rate changes to phenylephrine (1 and 3 
p.g/kg i.v.). For all studies, only SAD animals exhibiting a decline in 
heart rate of Ieu than 15 beats/min were selected. The drug injections 
i.v. and i.c.v. were maade as described in the previous section (dose-
response studies). 
Pretreatmeat &tudi•. In a separate group of rats the effects of 
varioua treatments on the hemodynamic responses to CGRP were 
teated. The treatments and doees of the druga are given in table 1. 
Atropine, BN 52021, cimetidine + pyrilamine, indomethacin and pro-
pranolol were injected i.v. 15 to 20 min before i.v. administration of 
CGRP at the doses of 1 or 10 nmolfkg; the SP-antagonist, [o-Pro2-D-
Phe7-o-Trp11]-SP was administered i.v. 5 min before CGRP. To 888Ure 
that the selected doees of the antagonists are sufficient to block the 
TABLE 1 
Tratmenta •nd doMs ot the drug• uud to moclty the 
hemodyMmlc rapon ... to r11t CGRP l.v. ln the conKiou• r11t 
PG, prostaglandtn; PPT-8P, (~-o-Phe7-o-Trp']-8P. 
Orug 
Beta-adrenoceptors 
Blocker Propranolol 
Museartnie receptors 
Blocker Atropine 
Histamine receptors 
Blockers H,: pyrtlanine 
H2: cimetidine 
Paf receptors 
Blocker BN 52021 
SP reoaptors 
Blocker PPT-5P 
PG cycloxygenase 
Inhibitor lndomethacln 
Dose,I.V. 
mgfkg 
2 
2 
2 
5 
15 
0.3 
5 
Trneof 
T1881menl 
min 
20 
20 
15 
15 
20 
5 
15 
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respective recepton, all these drugs were tested against their respective 
agonists. Thua, atropine (2 mg/kg) abolished the hemodynamic effects 
of acetylcholine (0.3-10 pgfkg i.v.); BN 52021 (15 mg/kg) blocked tbe 
hypotensive effect of Paf (0.3, 1 nmol/kg i.v.); cimetidine (5 mg/kg) 
and pyrilamine (2 mg/kg) aboliahed the vasomotor responses to hista-
mine (0.3-10 pg/kg i.v.); propranolol (2 mg/kg) blocked the hindquarter 
vaaodilator response to epinephrine (0.3, 1 pgfkg) and the tachycardia 
elicited by isoprenaHne (0.1, 0.3 pgfkg); the SP-antagonist PPT-SP 
(0.3 mg/kg i.v.) attenuated partially the cardiovaacular effects of SP 
(10, 100 nmol/kg). SP effects on both intestinaland vascular smooth 
muscle are attenuated by this antagonist (Pemow,1983). Indomethacin 
at the selected dose effectively blocks the prostaglandin synthesis 
(Flower, 197-t). 
Drugs used. The foUowing drugs were used: atropine sulfate (Amer-
ican Hospital Supply Co., McGaw Park, IL), CGRP (rat, Bachem, 
Torrance, CA), cimetidine hyd.rochloride (Sigma Chemical Co., St. 
Louis, MO), l-epinephrine (Sigma), indomethacin (Sigma), l-norepi-
nephrine {Sigma), phenylephrine (Sigma), dl-propranolol (Sigma), py-
rilamine (Smith Kline and French Laboratories, Philadelphia, PA), SP 
(Peninsula Laboratories, San Carlos, CA), [o-Pro2-o-Phe7-o-Trp9]-SP 
(Sigma) and BN 52021 [9H1,7a-(epoxymethano)-1H,6aH-cyclopenta 
[c ]furo[2,3-b)furo-[3' ,2' ,3,4]cyclopenta[1,2-d) furan-5,9,12-(4H)tri-
one, 3-tert-butylhexahydro-4,-7b, -llhydroxy-8 methyl). BN 52021 was 
kindly provided in a pure powder form by Dr. P. Braquet (IHB Research 
Laboratories, Paris, France). BN 52021 was fint dissolved in 50% 
dimethyl sulfoxide, the pH adjusted to 7 to 8 and diluted further with 
saline (0.9% NaCI w/v). lndomethacin was dissolved in 0.3 M Na2C03• 
All the other drugs were dissolved in saline. The peptides were ali-
quoted, stored at -2o•c, and thawed only once before ad.ministration. 
Statlatical analyais of the data. Data in ten and figures are mean 
::t: S.E. for the given number of rats. ANOVA with repeated measures 
(BMD P2V, Dixon and Brown, 1979), and ANOVA with Student-
Newman-Keul's test were used for statistical analysis of the data. 
Results 
Hemodynamic Effecta of l.v. Admlniatered Rat CGRP 
Effects on blood pressure and heart rate. The base-line 
values of MAP and heart rate were not different in saline- or 
CGRP-treated rats (table 2). CGRP doses of 1 and 10 nmol/kg 
decreased MAP and increased heart rate in a dose-related 
manner (fig. 1). At the 1-nmol/kg dose, the maximum decrease 
in blood pressure became apparent in 1 to 2 min after the 
injection and subsided in 15 to 30 min. The maximum increase 
in heart rate was achieved 2 min after the CG RP and subsided 
in 15 min. The 10-nmol/kg dose induced sustained hypotensive 
and tachycardiac responses which fully receded in 60 min. 
Effect& on cardiac index and TPRI. The 1-nmol/kg dose 
of CGRP induced a sustained increase in cardiac index (fig. 2). 
The maximum effect (+95 ± 16 ml/min/kg, P < .01) became 
apparent in 5 to 10 min after the injection but in three of seven 
animals the cardiac index was elevated significantly 60 min 
after the 1-nmol/kg dose. Thus, the base-line cardiac index 
before the 10-nmol/kg dose was significantly higher than in the 
saline-treated group (table 2). The 10-nmol/kg dose tended to 
decrease cardiac index of six of seven rats, including animals 
with normal base-line cardiac index (fig. 2). 
The hypotensive doses of CGRP (1 and 10 nmol/kg) de-
creased TPRI (fig. 2). The maximum reduction in TPRI was 
reached 2 to 5 min after the injections but the TPRI remained 
low over the 60-min observation period. The effect of CGRP 
on TPRI was dose-related in spite of the significantly lower 
base-line TPRI before the 10-nmol/kg dose (0.228 ± 0.02 
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TABLE2 
BaM-Une valuee ot hemoclynamlc parametera before admilllstratlon of Nllne or rat CGRP l.v. ln conecloue rate 
VIIlues lndlcate mean :t S.E. HA, heart rate; Cl, can:liac Index. 
n MAP 
mmHg 
SAUNE,I.v. 10 110 ± 3 
CGRP, 0.1 nmoiJkg 8 111 ± 4 
CGRP, 1 nmol/kg 8 107 ± 4 
CGRP, 10 nmoljkg 8 106 ± 5 
HA 
bpm 
389 ± 10 
403 ± 11 
392 ± 10 
406 ± 14 
Cl 
rN/miiJkg 
401 ± 14 
396 ± 15 
443 ± 18 
4ss·· ± 24 
TPRI 
mm HgJrN/mlnJI«J 
0.29 ± 0.02 
0.28 ± 0.02 
0.25 ± 0.01 
0.23• ± 0.02 
Asterisks denote statistlcal signific:ance va. saline (Student-Newman-Keul's test): • P < .05; •• P < .01. 
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Flg. 1. Effect of rat CGRP i.v. on MAP and heart rate (HR) in the 
oonscious rat. Vertical bars indicate S.E. Number of rats in each group 
is given in parenthesls. Astertsks derlote statistical significance vs. saline, 
i.v. by Student-Newman-Keut's test. 
mmHg/ml/min/kg vs. 0.29 ± 0.02 mm Hg/ml/min/kg in saline-
treated animals, P < .05). 
Effect& OD regional blood now. Figures 3 and 4 demon-
strate typical recordings of the effect of CGRP on arterial 
presaure and organ blood flow in the conscious rat. At the 0.1-
nmol/kg dose CGRP i.v. produced an increase in renal blood 
tlow (+19 ± 6%, P < .05) wbereas tbe higber doses produced 
variable effects on renal flow. Tbe maximum effect after tbe 
I 
D 
<J 
I 
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50 
0 
-50 
0.25 
i -0.25 
I' 
E 
E ! -0.50 
<J 
•• 
•• 
0 2 5 10 
* p < O.OS VI SALIIE 
•• , <0.01 
o SAUE (1-10) 
• CGRP 0.1aiMII/kg (I) 
• CGIP 11111111kl (I) 
• CGIIP 1 Olllllllq (I) 
30 ID 
TIME (lllil) 
Fig. 2. Effect of rat CGRP i. v. on cardiac Index (Cl) and TPRI in the 
conscious rat. Vertlcal bars indicate S.E. Number of rats in each group 
is given in parenthesls. Asterisks denote statistical signlficanoe vs. saline, 
l.v. by Student-Newman-Kaul's test. 
0.1-nmoljkg dose was acbieved 1 min after tbe injection and 
the effect subsided in 3 min. At this dose CGRP i.v. bad no 
effect on systemic arterial preBBure or mesenteric and hind-
quarter blood tlow (fig. 3). 
Tbe bindquarter blood tlow was increased by tbe CG RP 
doses of 1 and 10 nmol/kg by + 17 ± 5 and +27 ± 8% (P < .05 
vs. control), respectively (fig. 4). The peak effect was reached 1 
min after each injection and subsided in 5 min after tbe 1· 
nmol/kg dose. After the 10-nmolfkg dose, the hindquarter blood 
tlow was increased significantly (+20 ± 5%, P < .05) 10 min 
after the CGRP injection. 
In the mesenteric artery, CGRP doses of 1 and 10 nmol/kg 
first increased and tben decreased tlow (fig. 4). After the 1-
nmol/kg dose, tbe peak increase ( +30 ± 8%, P < .01 vs. control) 
in mesenteric blood tlow became apparent in 30 sec after CG RP 
administration and was followed 2 min later by a sustained 
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Flg. 3. A representative chart recording of the effect of rat CGRP (0.1 
nmol/kg i. v .) on arterial pressure (AP) and blood flow (BF) in the conscious 
rat. HO, hindquarter; R, renal; M, mesenteric. 
decrease ( -27 ± 6%, P < .05 vs. control) in flow whicb subsided 
in 30 min. Tbe corresponding cbanges in mesenteric flow after 
tbe 10-nmolfkg dose were +66 ± 11% (P < .01 vs. control) and 
-19 ± 7% (P < .05 vs. control), respectively. 
All the hemodynamic responses produced by the 10-nmol/kg 
dose of CGRP were significantly morepotent (P < .01) than 
those elicited by the same dose of SP (fig. 4). At the 10-nmol/ 
kg dose, SP bad no significant effect on arterial pressure or 
heart rate but induced vasodilator responses in each vascular 
bed. Tbe maximum increases in blood flow in tbe renal, hind-
quarter and mesenteric vessels were + 10 ± 2, +21 ± 4 (P < 
.01) and +24 ± 4% (P < .01), respectively. The corresponding 
changes in vascular resistance were -17 ± 2 (P < .01), -22 ± 
4 (P < .01) and -23 ± 4% (P < .01). The 100-nmol/kg dose of 
SP decreased mean arterial pressure (-19 ± 6 mmHg, P < .01) 
and increased beart rate ( +67 ± 18 bpm, P < .05) with regional 
hemodynamic changes similar to the 10-nmol/kg dose. At lower 
doses SP had no significant effect on any of the bemodynamic 
variables. 
Elfeeta of regional VBIICular resistance. At the 1- and 
10-nmolfkg doses, CGRP i.v. decreased vascular resistance in 
the hindquarter, renal and mesenteric blood vessels (fig. 5). 
The lowest dose (0.1 nmolfkg) produced a significant decrease 
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in renal resistance (-15 ± 4%, P < .05) but bad no effect on 
vascular resistance in the other vascular beds (fig. 5). The 
maximum changes in vascular resistance became apparent si-
multaneously with tbe peak blood flow 30 sec to 2 min after 
the drug injection. In the mesenteric and renal vasculature, the 
vasodilation subsided within 10 min after the 10-nmol/kg dose 
whereas tbe hindquarter resistance was still decreased ( -25 ± 
4%, P < .05) 30 min after the highest dose of CGRP. Although 
the mesenteric blood flow was reduced after the initial increase 
in blood flow, mesenteric vascular resistance was never signif-
icantly increased. 
Role of other mediaton in the hemodynamic effects of 
CGRP. The various treatments tested toblock hemodynamic 
responses to CGRP i.v. are shown in table 1. None of these 
treatmentsbad any significant effect on the base-line values of 
cardiovascular variables before CG RP administration. The beta 
adrenoceptor blocker propranolol attenuated the tachycardia 
produced by CGRP but bad no effect on the hypotensive and 
vasodilator responses to CGRP (table 3). All tbe other treat-
ments failed to significantly alter the hemodynamic responses 
produced by CGRP i.v. (table 3). 
Effect& of CGRP after sinoaortic denervation. The 
base-line MAP (145 ± 6 mm Hg) and heart rate (492 ± 8 bpm) 
in SAD rats were significantly (P < .01) higher than in intact 
rats (112 ± 3 mm Hg and 381 ± 16 bpm, respectively), whereas 
there was no significant differences in the base-line blood flow 
or vascular resistance between these groups.ln SAD rats CGRP 
i.v. (0.1-1 nmol/kg) produced hypotension with no significant 
effect on the heart rate. The depressor responses to CGRP 
doses of 0.1 and 1 nmolfkg were significantly magnified in SAD 
rats compared to the responses in intact animals (fig. 6). The 
tachycardic effect of the 1-nmol/kg dose was attenuated in 
SAD rats compared to intact rats (fig. 6). At the lower doses 
CGRP i.v. bad no significant effect on heart rate in either 
intact or baroreceptor-denervated animals. 
The vasodilator responses of all three vascular beds to the 1-
nmolfkg dose of CGRP i. v. were significantly enhanced in SAD 
rats compared to intact rats (fig. 7). In the mesenteric artery, 
even the 0.1-nmol/kg dose produced a significant decrease in 
vascular resistance in the SAD rats. 
Effects of centrally administered CGRP. The effects of 
i.c.v. administration of CGRP (0.1-10 nmol/kg) on hemody-
namic variables are summarized in table 4. The 10-nmol/kg 
dose of CGRP i.c.v. produced a moderate increase in heart rate 
in intact rats but bad no effect on blood pressure or organ blood 
flow. In SAD rats, CGRP (i.c.v. doses of 1 and 10 nmolfkg) 
elicited tachycardia. After baroreceptor deafferentation, the 
blood pressure tended to increase by CGRP i.c.v. (0.1-10 nmol/ 
kg) but the effect did not reach statistical significance when 
compared to vehicle injection. 
Discussion 
The hypotensive and tacbycardic effects of CGRP i.v. have 
been described in several species including humans (DiPette et 
al., 1987; Fisher et al., 1983; Franco-Cereceda et al., 1987; Lappe 
et aL, 1987; Marshall et al., 1986b). Previous studies have 
suggested that the hypotensive action of CG RP is due to 
generalized vasodilation. Thus, intradermal injections of hu-
man or rat CG RP of less than picomolar doses produced 
sustained local vasodilation in the rabbit ear or human skin 
(Brain et al., 1985; Brain and Williams, 1986) and elicited 
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relaxation of vascular smooth muscle in vitro (Brain et al., 1985; 
Hanke et al., 1985; Marshallet al., 1986a). The present study 
provides direct evidence that the hypotension produced by 
CGRP in vivo is due to reduced total peripheral resistance and 
sustained vasodilation in hindquarter, mesenteric and renal 
vasculature. 
In the mesenteric artery, CGRP produced a biphuic blood 
flow response: a transient increase in flow followed by a sus-
tained reduction. However, the mesenteric resistance wu al-
ways decreased after CG RP. The mesenteric vuodilation pre-
ceded the hypotensive response indicating that the decrease in 
mesenteric resistance probably contributed to the hypotension. 
CGRP was reported to produce splanchnic vuodilation in the 
conscious rat in recent studies by DiPette et al. (1987) and 
Lappe et al. (1987). The spienie vessels of the rat, however, 
were shown to respond to CGRP injections with vasoconstric-
tion (DiPette et al., 1987). Thus, the regional vuomotor re-
sponses to CGRP even in a restricted area such 88 the splanch-
nic region might be very diverse. The blood vessels in the 
gastrointestinal tract have been demonstrated to be lavishly 
innervated with CGRP-immunoreactive fibers (Mulderry et al., 
1985). The highest accumulation of these nerve fibers were 
found in the adventitia and muscle layers of the superior 
mesenteric artery (Mulderry et al., 1985). Although the CGRP 
receptor distribution in the peripheral blood vessels is not 
known at the present time, it appears that high Ievels of CGRP 
immunoreactivity in the gutrointestinal blood vessels areweil 
in accordance with the responsiveness of vasculature to the 
vuodilator action of CGRP in vivo. 
The lowest dose of CGRP (0.1 nmol/kg) produced a selective 
increase in renal blood flow with no effect on systemic blood 
pressure or blood flow in the other vascular beds. At higher 
doses, the renal flow tended to decrease due to the fall in 
systemic pressure. The reduction in arterial pressure always 
exceeded the decrease in renal blood flow and the renal vascular 
resistance was reduced consistently by all doses of CGRP. In 
this regard our results contradict the findings of a recent study 
in which CGRP bad no effect on renal resistance and a decrease 
in renal flow paralleled the systemic hypotension produced by 
similar doses (0.2 and 6 nmol/kg) of CGRP (DiPette et al., 
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TABLE3 
lnfluence of •troplne, P•f·•nt8gonlat BN 52021, clmetldlne + pyrll8mlne, lnclometh8cin, propr8nolol orthe SP-•ntagonlat PPT·SP on the 
helnodyMmlc fMponaH to 1111 CGRP (10 rwnol/kg/l.v.) ln conadoua 111ta 
Values (mean :t S.E.) lnclcate rnamun chenges 2 to 5 nin alter GCRP. HR, heart rate; BF, blood ftow; VR, vasaJIIr resistance; HO. hlndquarter; R. renal; M, 
maent.-tc; CIM, cimetidine; PYRIL, pyrilamhe; PPT-5P, (o-PI'ct-o-Phe7-o-Trp~. 
Tn181nalt n ~MAP ~HR 
CGRP 16 -59 +120 
±5 ±23 
CGRPafter 8 -54 +108 
atropine ±9 ±26 
CGRPafter 7 -57 +83 
BN 52021 ±10 ±15 
CGRPafter 9 -41 +106 
CIM+PYRIL ±3 ±16 
CGRPafter 7 -62 +94 
lndomethacin ±5 ±23 
CGRPafter 6 -64 +42•• 
propranolol ±8 ±20 
CGRPafter 7 -52 +83 
PPT.SP ±5 ±23 
1987). In the study of DiPette et aL (1987), the blood flow was 
monitored only at one time point, 3 min after the CG RP 
administration, and the initial renal vasodilation most probably 
was misaed. Thus, our data underscore the usefulness of the 
Doppler velocimetry in monitoring instantaneous and transient 
vasomotor responses which otherwise might not be detected. 
CGRP i.v. produced vasodilator responsesalso in the hind-
quarter (mainly skeletal muscle) blood vessels. This rmding is 
in accordance with the recent reports which demoostrate vaso-
dilator responses in skeletal muscle blood vessels in the con-
scious rat (DiPette et aL, 1987; Lappe et al., 1987). In these 
previoua studies, the time-responserelationship of the vasodi-
lator response was not eumined. Our present study revealed a 
sustained hindquarter vasodilation and increase in hindquarter 
blood flow at times at which hypotension already counteracted 
~%8f ~%VR 
HO R M HO R M 
+30 +5 +66 -48 -42 -53 
±6 ±6 ±11 ±4 ±5 ±3 
+25 +18 +60 -52 -45 -59 
±13 ±6 ±16 ±9 ±9 ±8 
+25 +3 +27 -61 -43 -37 
±9 ±9 ±10 ±4 ±10 ±4 
±51 +21 +42 -55 -46 -35 
±15 ±7 ±13 ±5 ±4 ±14 
+28 +9 +30 -63 -53 -56 
±12 ±11 ±12 ±4 ±8 ±7 
+34 +18 +33 -64 -46 -66 
±8 ±10 ±10 ±4 ±9 ±8 
+42 +16 +55 -58 -43 -50 
±10 ±7 ±11 ±5 ±8 ±5 
the vasodilation induced increase in the renal and mesenteric 
blood flow. 
The hypotensive and vasodilator effecta of the 1-nmol/kg 
dose of CGRP were accompanied by a strong tachycardia and 
an increase in card.iac output. At the highest dose the card.iac 
output tended to decrease in spite of the profound positive 
chronotropic response and decreased card.iac afterload. This 
may be due to the decrease in venous retum caused by the 
extreme peripheral vasodilation and reduction in total periph-
eral resistance. A direct cardiac depressor effect is not likely as 
CGRP has been shown to increase card.iac frequency and con-
tractility in the isolated rat heart (Asimakis et aL, 1987; Lund-
berg et aL, 1985; Marshall et aL, 1986b; Saito et al., 1986), and 
to elicit coronary vasod.ilation in the pig or rat (Asimakis et aL, 
1987; Ezra et aL, 1987; Holman et aL, 1986). The stimulation 
76 Sir8n and Feue,.tein 
MEAN ARTERIAL PRESSURE 
* 
~Saline 
-60 CJ CGRP·Intact 
•cGRP·SAD 
* p< 0.05 
-80 * * p< 0.01 
0.1nmoUkg 
+ 150 
HEART RATE 
c + 100 ~ 
fti 
l 
~ +50 
1 nmoUkg 
* * * * r----,,--, 
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after CGRP injections. Each group comprised six rats. Asterisks denote 
statistical significance by Student-Newman-Keul's test. 
of sympathetic outflow by CGRP in humans (Franco-Cereceda 
et al., 1987) also contradicts a negative inotropic action. 
The hypotension and splanchnic vasodilator responses to 
CGRP i.v. were significantly enhanced in SAD rats compared 
to intact animals. These results indicate clearly that CGRP 
produces hypotension by directly relaxing the peripheral re· 
sistance vessels rather than by interfering with the baroreflex 
circuits. In fact, the failure of the 0.1-nmol/kg dose to elicit 
changes in arterial pressure was probably due to the cardiovas-
cular stimulation caused by baroreceptor activation inasmuch 
as removal of the baroreflex mechanisms resulted in a strong 
depressor response even at this low dose of CGRP. Typical for 
•DOUAIITEII 
+ 5 IIESISTANCE 
- 10 
-20 
rlS1Iitt1 
Vol. 247 
a peripherally acting vasodilator agent, the tachycardic effect 
of CGRP was reduced after baroreceptor deafferentation. Al-
though the higher resting Ievel of heart rate in SAD rats 
compared to intact animals might have contributed to the 
reduced tachycardic response, the primary reason for the atten-
uation of CGRP-induced tachycardia was obviously the Iack of 
baroreceptor stimulation, as heart rate can be increased mark-
edly in SAD rats by other stimuli such as central injections of 
thyrotropin releasing hormone (Siren et al., 1988). 
A reflex activation of the sympathetic nervous system as a 
mechanism for the tachycardiac action of CGRP i.v. is sup-
ported also by the attenuation of the tachycardia by the beta-
adrenoceptor blocker, propranolol. However, a central nervous 
system activation of sympathetic outflow probably contributed 
to the cardiac acceleration as CGRP also produced a moderate 
increase in heart rate after i.c.v. administration. This assump-
tion is supported further by the studies showing increases in 
plasma norepinephrine after i.c.v. administration of CGRP in 
the rat (Fisher et al., 1983). A tendency for tachycardia was 
also found after the 0.1-nmol/kg dose which had no effect on 
arterial pressure. CGRP i.v. was still capable of producing 
hypotensive and tachycardic responses in the pithed rat which 
completely Iacks the centrat nervous system (Haass and Sko-
fitissch, 1985). CGRP increased frequency and contractility of 
isolated heart muscle (Lundberg et al., 1985; Marshall et al., 
1986b; Saito et al., 1986). Thus, a direct cardiac action might 
also contribute to the tachycardia produced by CG RP. 
The hypotensive and vasodilator effects of CG RP were not 
influenced by drugs which block beta adrenergic, muscarinic, 
histamine, SPor Paf receptors or the synthesis of prostaglan-
dins. CG RP was shown to potentiate the plasma extravasation 
and skin edema produced by other proinflammatory mediators 
such as bradykinin, leukotriene B., Paf or SP (Brain and 
Williams, 1985) but the vasorelaxing effect of CGRP was never 
blocked by receptor blockers or synthesis inhibitors of other 
mediators including acetylcholine, histamine, Paf or prosta-
glandins (Brain et al., 1985; Marshallet al., 1986ab). Our data 
are in accord with and extend these observations which indicate 
clearly that the vascular actions of CGRP i.v. are mediated by 
a direct action on CGRP receptors. 
The potency of CG RP to induce hypotensive and vasodilator 
responses in the conscious rat was at least 10-fold that of SP. 
The same was also true of the ability of the peptides to produce 
tachycardia. Previous studies have shown that SP is one of the 
most potent vasodilator mediators (Pernow, 1983). In a pre-
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TABLE4 
M8xlmum hernodyn8rnic responMa to CGRP l.c.v. ln conacloua 
lntKt and SAD rate 
HR, heart rate; BF, blood flow; VR, vascular resistance; HO, hindquarter; R, renal; 
M, mesenteric. 
41BF(%) 41VR(%) 
HO R M HO R M 
lntact 
Saline, l.c.v. +5 -7 +6 0 +2 +1 +2 -1 
±4 ±16 ±7 ±2 ±2 ±5 ±3 ±4 
0.1 nmol/kg i.c.v. +3 -11 +8 -9 +10 -5 +14 -3 
±3 ±8 ±4 ±4 ±8 ±4 ±5 ±5 
1 nmol/kg i.c. v. +7 +33 +6 +2 -6 -4 +1 +15 
±7 ±16 ±4 ±1 ±4 ±3 ±2 ±9 
10 nmol/kg i.c.v. +7 +78 +15 -8 -5 -10 +15 +11 
±2 ±37• ±5 ±4 ±5 ±4 ±6 ±4 
SAD 
Saline, i.c.v. +5 -28 -2 0 0 0 -3 +8 
±3 ±9 ±2 ±0 ±2 ±5 ±4 ±8 
0.1 nmol/kg i.c.v. +18 -11 +13 -8 -10 -7 +12 +28 
±4 ±20 ±8 ±4 ±5 ±6 ±8 ±9 
1 nmol/kg i.c. v. +14 +36·· +19 -7 -11 -13 +16 +24 
±5 ±9 ±5 ±4 ±4 ±5 ±5 ±11 
10 nmol/kg i.c.v. +19 +52•• +7 -2 -4 +7 +48 +20 
±8 ±10 ±5 ±5 ±2 ±9 ±12 ±8 
• P < .05; •• P < .01 vs. saline (Student-Newman-Keuls' test). 
vious study in the pithed rat, CGRP was 10-fold more potent 
to produce hypotension than SP but bad Ieu than one-third of 
the potency of SP to cause plasma extravasation (Haau and 
Skofitisch, 1985). CGRP wasmorepotent than SP to induce 
dilation in the rabbit microvasculature (Ohlen et al., 1987). In 
the rat skin, SP was shown to potentiate CGRP-induced edema 
(Brain and Williams, 1985). CGRP and SP are colocalized in 
the perivascular nerves of the vascular tissue (Lundberg et al., 
1985, Uddman et al., 1986; Öhlen et al., 1987). These data taken 
together suggest that participation of both CGRP and SP in 
vascular responses to sensory nerve stimulation. CGRP and SP 
are probably acting in an additive manner and the effects of 
CGRP seem tobe independent of SP release as the SP antag-
onist failed to modify any of the hemodynamic changes pro-
duced by CGRP. Our data are supported by the recent obser-
vations that the effects of SP but not those of CG RP were 
blocked by the SP-antagonist, spantide, in the guinea pig 
arterioles (Uddman et al., 1986). The Iack of a CGRP antago-
nist, however, makes it difficult to evaluate the role of CGRP 
in vascular responses to SP. 
Administration of CGRP into the cerebral ventricles elicited 
a modest tachycardic response but was devoid of any other 
hemodynamic actions in the conscious rat. Our data contradict 
the fmdings by Fisher et aL ((1983) which showed marked 
increases in heart rate and plasma epinephrine content together 
with a moderate pressor response after i.c. v. injections of equal 
doses of CGRP in the conscious rat. Mild tachycardia (+60 
bpm) and a slight hypertenaive reaponae ( + 10 mm Hg) was 
also found after local application of CG RP into the central 
amygdaloid nucleus of the halothane-anesthetized rat (Nguyen 
et al.' 1986) but these rmdings are difficult to interpret due to 
the eJ:tremely slow onset of the responses (the effects became 
apparent 30 to 40 min after CGRP administration) and the 
relatively high injection volume (200 nl). There is no clear 
explanation for the discrepancy between our data and the 
earlier rmdings (Fisher et al., 1983). Technical problemssuch 
as a misplacement of the i.c. v. cannula were not the reason for 
the Iack of effect of CGRP in our study, as the injection into 
the ventricular space was confinned after each experiment with 
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an injection of dye into the cannula. In addition to CGRP, 
every rat was tested with the centrally active agent, thyrotropin 
releasing hormone which consistently produced a strong pres-
sor/tachycardic response (Siren et al., 1988). CGRP was diluted 
fresh each day and was capable of producing the full scope of 
cardiovascular responses after systemic (i.v.) administration at 
lower doses than those used in the i.c.v. 
In conclusion, the present study shows that systemic admin-
istration of CGRP decreases arterial pressure by reducing vas-
cular resistance in mesenteric, renal and hindquarter skeletal 
muscle blood vessels. The hypotensive and vasodilator actions 
of CGRP i.v. are most likely mediated by a direct action on 
peripheral vasculature, whereas the tachycardic response seems 
to be dependent primarily upon reflex activation of the sym-
pathetic outflow. In conjunction with the earlier neuroanatom-
ical data, our findings suggest a role for CG RP as a local 
regulator of peripheral vascular tone and regional blood flow 
but unlike previous reports do not support a role for CG RP in 
the central cardiovascular control. The strong vasodilator po-
tency of CG RP may warrant a therapeutic role for this peptide 
in clinical situations in which the selective regional vasodilation 
and increase in cardiac output are desired (e.g. congestive heart 
failure). These hypotheses, however, await further investiga-
tion. 
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